Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06961669 | Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma(ECAR01) | recruiting | N/A | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT06718244 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT06869265 | Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia | recruiting | Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06972641 | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | Phase 2 / Phase 3 | 126 | Ruijin HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06034561 | Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06138990 | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML(RAPID-01) | recruiting | Phase 2 | 88 | ETH ZurichOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06849401 | The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 15, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06697327 | Daunorubicin + Cytarabine + Venetoclax in de Novo AML | enrolling by invitation | N/A | 94 | Anhui Medical UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05124288 | Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways(GITMO-RELAPSE) | recruiting | — | 500 | Ciceri FabioOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04202835 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | active not recruiting | Phase 2 | 80 | McMaster UniversityOTHER | 2 | May 11, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT05959720 | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil(BRALLA) | recruiting | — | 180 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | recruiting | Phase 2 | 59 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03509961 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | recruiting | Phase 2 | 95 | Pediatric Transplantation & Cellular Therapy ConsortiumOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04836390 | Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant(EXCEL) | enrolling by invitation | Phase 2 | 30 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03898596 | Umbilical Vessel Catheterization Under ECG Monitoring and Guidance | recruiting | N/A | 150 | Stanford UniversityOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06947044 | Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding(BAIT) | recruiting | N/A | 60 | Donald ArnoldOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT06937554 | Evaluation of Functional and Nutritional Parameters in Fit Acute Leukemia Patients(FisNutEma) | recruiting | — | 30 | University of Rome Tor VergataOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06938009 | Dutch Registry of Pediatric Cardiac Arrest(PROGNOSE) | recruiting | — | 500 | Matthijs de HoogOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial(MAST) | recruiting | Phase 2 | 50 | Imperial College LondonOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06537726 | Breath Analysis for the Detection of Invasive Fungal Infections(REDEFINE) | recruiting | — | 130 | University of ZurichOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03439371 | Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia(MTSA) | recruiting | N/A | 21 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06166706 | Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia(BIG APPLE) | recruiting | — | 10,000 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT06918054 | Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia | recruiting | Phase 4 | 42 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06919393 | "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL(TRINEG-ALL) | recruiting | — | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 | clinicaltrials |
| NCT04233346 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | active not recruiting | Phase 2 | 93 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03918655 | MIF Involvement in AML(MIFAML) | active not recruiting | — | 186 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05558943 | Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital(LAMSA) | not yet recruiting | — | 750 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06902025 | JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia | not yet recruiting | N/A | 24 | He HuangOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899581 | Gut Health in Children With Cancer | recruiting | — | 40 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06900088 | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients | not yet recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06022003 | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia(OGILAR) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06891144 | Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy | recruiting | — | 1,000 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06892223 | Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation | recruiting | Phase 2 | 42 | Istituto Clinico HumanitasOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06885476 | Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients | recruiting | N/A | 22 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06886074 | Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL | recruiting | Phase 2 | 30 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT03507842 | A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. | enrolling by invitation | Phase 3 | 380 | Asan Medical CenterOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2025source: clinicaltrials